Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
Patrick A. Ott(Dana-Farber Cancer Institute), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Pamela N. Münster(University of California, San Francisco), Michael J. Pishvaian(Georgetown University), Emilie M.J. van Brummelen(The Netherlands Cancer Institute), Roger B. Cohen(University of Pennsylvania), Carlos Gomez‐Roca(Institut Claudius Regaud), Samuel Ejadi(Pinnacle Oncology Hematology), Mark N. Stein(Rutgers, The State University of New Jersey), Emily Chan(Vanderbilt University), Matteo Simonelli(Humanitas University), Anne Morosky(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sanatan Saraf(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kenneth Emancipator(Merck & Co., Inc., Rahway, NJ, USA (United States)), Minori Koshiji(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jaafar Bennouna(Institut de Cancérologie de l'Ouest)
Cited by 252Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis